82 results
8-K
EX-99.1
VRNA
Verona Pharma Plc
9 May 24
Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:22am
of 2024, the Company will continue to highlight the burden of chronic obstructive pulmonary disease ("COPD") through the "Unspoken COPD" disease … and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. In the third quarter
8-K
VRNA
Verona Pharma Plc
9 May 24
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
7:18am
, the potential for ensifentrine to be the first novel inhaled mechanism for the maintenance treatment of chronic obstructive pulmonary disease in more than 20
8-K
EX-99.1
sm2djrp0
9 May 24
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
7:18am
PRE 14A
7tsgq0 9ob24zjsg
8 Mar 24
Preliminary proxy
4:18pm
8-K
EX-99.1
w2e854afplwoc5l9dtnl
29 Feb 24
Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
6:08am
8-K
EX-99.1
qo7ehgbn4eax67f eo01
2 Jan 24
Strengthens financial flexibility to support the Company’s continued growth
6:02am
8-K
EX-10.1
xdzo1u1m8
2 Jan 24
Strengthens financial flexibility to support the Company’s continued growth
6:02am
8-K
EX-99.1
r1zgv2vew rh9r5s
2 Nov 23
Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update
6:24am
8-K
2mirf y3n3bn3
11 Sep 23
Other Events
6:02am
8-K
EX-99.1
buo sb3g7
3 Aug 23
Verona Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update
6:11am
8-K
EX-99.1
gojvljf7cp fr
9 May 23
Verona Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update
6:13am
8-K
nu3gxzyb2roy2hq
20 Dec 22
Regulation FD Disclosure
6:02am